|
1
|
American Cancer Society. Cancer Facts
& Figures 2013. American Cancer Society Inc. http://www.cancer.org.
Atlanta: 2013
|
|
2
|
Haruta S, Furukawa N, Yoshizawa Y, Tsunemi
T, Nagai A, Kawaguchi R, Tanase Y, Yoshida S and Kobayashi H:
Molecular genetics and epidemiology of epithelial ovarian cancer
(Review). Oncol Rep. 26:1347–1356. 2011.PubMed/NCBI
|
|
3
|
Heintz AP, Odicino F, Maisonneuve P, Quinn
MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U:
Carcinoma of the ovary. FIGO 26th Annual Report on the Results of
Treatment in Gynecological Cancer. Int J Gynaecol Obstet Off Organ
Int Fed Gynaecol Obstet. 95:S161–S192. 2006. View Article : Google Scholar
|
|
4
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, et al: Rethinking ovarian cancer: recommendations
for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jones S, Wang TL, Shih IeM, Mao TL,
Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, et
al: Frequent mutations of chromatin remodeling gene ARID1A in
ovarian clear cell carcinoma. Science. 330:228–231. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y
and Al E: ARID1A mutations in endometriosis-associated ovarian
carcinomas. N Engl J Med. 363:1532–1543. 2011. View Article : Google Scholar
|
|
7
|
Bell D, Berchuck A, Birrer M, Chien J,
Cramer D, Dao F, Dhir R, Di Saia P, Gabra H, Glenn P, et al:
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar
|
|
8
|
Kanchi KL, Johnson KJ, Lu C, McLellan MD,
Leiserson MD, Wendl MC, Zhang Q, Koboldt DC, Xie M, Kandoth C, et
al: Integrated analysis of germline and somatic variants in ovarian
cancer. Nat Commun. 5:31562014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kalamanathan S, Bates V, Lord R and Green
JA: The mutational profile of sporadic epithelial ovarian
carcinoma. Anticancer Res. 31:2661–2668. 2011.PubMed/NCBI
|
|
10
|
Kurman RJ and Shih I-M: Molecular
pathogenesis and extraovarian origin of epithelial ovarian cancer -
shifting the paradigm. Hum Pathol. 42:918–931. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tuefferd M, Couturier J, Penault-Llorca F,
Vincent-Salomon A, Broët P, Guastalla JP, Allouache D, Combe M,
Weber B, Pujade-Lauraine E, et al: HER2 status in ovarian
carcinomas: A multicenter GINECO study of 320 patients. PLoS One.
2:e11382007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ahmed AA, Etemadmoghadam D, Temple J,
Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio
A, et al: Driver mutations in TP53 are ubiquitous in high grade
serous carcinoma of the ovary. J Pathol. 221:49–56. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuo KT, Mao TL, Jones S, Veras E, Ayhan A,
Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ and Shih IeM:
Frequent activating mutations of PIK3CA in ovarian clear cell
carcinoma. Am J Pathol. 174:1597–1601. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamamoto S, Tsuda H, Takano M, Iwaya K,
Tamai S and Matsubara O: PIK3CA mutation is an early event in the
development of endometriosis-associated ovarian clear cell
adenocarcinoma. J Pathol. 225:189–194. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Singer G, Oldt R, Cohen Y, Wang BG,
Sidransky D, Kurman RJ and Shih I-M: Mutations in BRAF and KRAS
characterize the development of low-grade ovarian serous carcinoma.
J Natl Cancer Inst. 95:484–486. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gemignani ML, Schlaerth AC, Bogomolniy F,
Barakat RR, Lin O, Soslow R, Venkatraman E and Boyd J: Role of KRAS
and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol
Oncol. 90:378–381. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mayr D, Hirschmann A, Löhrs U and Diebold
J: KRAS and BRAF mutations in ovarian tumors: a comprehensive study
of invasive carcinomas, borderline tumors and extraovarian
implants. Gynecol Oncol. 103:883–887. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen JS, Lan K and Hung MC: Strategies to
target HER2/neu overexpression for cancer therapy. Drug Resist
Updat. 6:129–136. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ross JS: Disease-free survival according
to degree of HER2 amplification for patients treated with adjuvant
chemotherapy with or without 1 year of trastuzumab: the HERA trial.
Breast Dis. 21:378–380. 2010.
|
|
20
|
Bang YJ, van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): a phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Carpten JD, Faber AL, Horn C, Donoho GP,
Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage
S, et al: A transforming mutation in the pleckstrin homology domain
of AKT1 in cancer. Nature. 448:439–444. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Anastas JN and Moon RT: WNT signalling
pathways as therapeutic targets in cancer. Nat Rev Cancer.
13:11–26. 2013. View Article : Google Scholar
|
|
23
|
Ascierto PA, Schadendorf D, Berking C,
Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck
JT, St-Pierre A, et al: MEK162 for patients with advanced melanoma
harbouring NRAS or Val600 BRAF mutations: a non-randomised,
open-label phase 2 study. Lancet Oncol. 14:249–256. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Janku F, Wheler JJ, Naing A, Falchook GS,
Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, et al:
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR
signaling pathway inhibitors in early phase clinical trials. Cancer
Res. 73:276–284. 2013. View Article : Google Scholar :
|
|
25
|
Jänne PA, Shaw AT, Pereira JR, Jeannin G,
Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V,
Smith P, et al: Selumetinib plus docetaxel for KRAS-mutant advanced
non-small-cell lung cancer: a randomised, multicentre,
placebo-controlled, phase 2 study. Lancet Oncol. 14:38–47. 2013.
View Article : Google Scholar
|
|
26
|
Sheppard KE and McArthur GA: The
cell-cycle regulator CDK4: an emerging therapeutic target in
melanoma. Clin Cancer Res. 19:5320–5328. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hutson TE, Escudier B, Esteban E,
Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR,
Hariharan S, et al: Randomized phase III trial of temsirolimus
versus sorafenib as second-line therapy after sunitinib in patients
with metastatic renal cell carcinoma. J Clin Oncol. 32:760–767.
2014. View Article : Google Scholar
|
|
28
|
Gordon GM, Zhang T, Zhao J and Du W:
Deregulated G1/S control and energy stress contribute to the
synthetic-lethal interactions between inactivation of RB and TSC1
or TSC2. J Cell Sci. 126:2004–2013. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yamamoto S, Tsuda H, Takano M, Tamai S and
Matsubara O: PIK3CA mutations and loss of ARID1A protein expression
are early events in the development of cystic ovarian clear cell
adenocarcinoma. Virchows Arch. 460:77–87. 2012. View Article : Google Scholar
|
|
30
|
Janku F, Wheler JJ, Westin SN, Moulder SL,
Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna
I, et al: PI3K/AKT/mTOR inhibitors in patients with breast and
gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol.
30:777–782. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yan M, Parker BA, Schwab R and Kurzrock R:
HER2 aberrations in cancer: implications for therapy. Cancer Treat
Rev. 40:770–780. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McAlpine JN, Wiegand KC, Vang R, Ronnett
BM, Adamiak A, Köbel M, Kalloger SE, Swenerton KD, Huntsman DG,
Gilks CB, et al: HER2 overexpression and amplification is present
in a subset of ovarian mucinous carcinomas and can be targeted with
trastuzumab therapy. BMC Cancer. 9:4332009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miller CR, Oliver KE and Farley JH: MEK1/2
inhibitors in the treatment of gynecologic malignancies. Gynecol
Oncol. 133:128–137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Koshiyama M, Matsumura N, Baba T,
Yamaguchi K, Yoshioka Y and Konishi I: Two cases of recurrent
ovarian clear cell carcinoma treated with sorafenib. Cancer Biol
Ther. 15:22–25. 2014. View Article : Google Scholar :
|
|
35
|
Bartholomeusz C, Oishi T, Saso H, Akar U,
Liu P, Kondo K, Kazansky A, Krishnamurthy S, Lee J, Esteva FJ, et
al: MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of
ovarian clear cell carcinoma in a PEA-15-dependent manner in a
mouse xenograft model. Mol Cancer Ther. 11:360–369. 2012.
View Article : Google Scholar :
|
|
36
|
Muller PA and Vousden KH: Mutant p53 in
cancer: new functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Honig A, Hahne JC, Meyer S, Kranke P,
Häusler S, Diessner J, Dietl J and Engel JB: PI3K inhibitor
D-116883 is effective in in vitro models of ovarian cancer.
Anticancer Res. 32:2035–2041. 2012.PubMed/NCBI
|
|
38
|
Chan DA and Giaccia AJ: Harnessing
synthetic lethal interactions in anticancer drug discovery. Nat Rev
Drug Discov. 10:351–364. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Helming KC, Wang X, Wilson BG, Vazquez F,
Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ,
et al: ARID1B is a specific vulnerability in ARID1A-mutant cancers.
Nat Med. 20:251–254. 2014. View Article : Google Scholar : PubMed/NCBI
|
